Overview:

Aclidinium bromide (Tudorza Pressair™) is a drug recently approved by the FDA for chronic obstructive pulmonary disease (COPD). The drug is administered via inhalation and requires a sensitive LC-MS/MS method for the simultaneous quantification of aclidinium and its two inactive metabolites, LAS 34850 and LAS 34823, in human plasma, namely 5 pg/mL. Significant efforts in plasma sample extraction method to eliminate interference peaks and allow proper quantification of Aclidinium and LAS 34823 were not successful. After diligent optimization of key SelexION™ Technology differential ion mobility parameters, scientists were able to successfully eliminate the interferences peaks without sacrificing the sensitivity. This webinar will review the key LC-MS/MS SelexION™ parameters that were used in the final method using methanol as chemical modifier.